FGL vs Noopept
A side-by-side research comparison of FGL and Noopept across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FGL | Noopept |
|---|---|---|
| Full name | FGL (NCAM-Derived Peptide) | Noopept (GVS-111) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Mimics NCAM FG loop interacting with FGFR1 to promote LTP, neurite outgrowth, neuronal survival, and presynaptic function enhancement. | Metabolized to cycloprolylglycine which modulates AMPA/NMDA receptors. Increases NGF and BDNF in hippocampus/cortex. Antioxidant neuroprotection and acetylcholine enhancement. |
| Molecular weight | ~1,800 Da | 318.4 Da |
| Half-life | 4-8 hours | 30-60 minutes (active metabolite longer) |
| Bioavailability | Moderate (SubQ, partial BBB crossing) | High (oral/sublingual) |
| Typical dose | 1-5 mg/kg (research) | 10-30 mg |
| Frequency | Daily or every other day | 2-3x daily |
| Route | Subcutaneous | Oral or Sublingual |
FGL reported benefits
- Synaptic plasticity
- LTP facilitation
- Memory improvement
- Neurotrophic effects
- FGFR activation
Noopept reported benefits
- Enhanced memory/learning
- Neuroprotection
- BDNF/NGF increase
- Improved focus
- Anxiolytic
- Low dose requirement
Related comparisons
Research and educational reference only. Not medical advice.